Rafael Martín-Masot, MD, *Pilar Ortiz Pérez, MD, *Encarnación Torcuato Rubio, MD,
*Javier Blasco Alonso, PhD, *Marta Herrador López, †Carmen Gallego Fernández, PhD,
and *Víctor Manuel Navas-López, PhD, DOI: 10.1097/PG9.0000000000000100
Scientific corner
The New Molecules Are Changing the Course of Pediatric Chronically Active Ulcerative Colitis: A Series of Pediatric Cases
Chronically active ulcerative colitis (UC) constitutes a challenge in an era where medical therapeutic options have increased while experience with colectomies has decreased. The change in the therapeutic paradigm of the disease means that patients with chronically active UC are being managed waiting to find their therapeutic target. We present 2 cases of children with chronically active UC who did not respond to intravenous steroids nor sequential therapy. A response was obtained with ustekinumab and tofacitinib, 2 drugs widely used in adults but still with little evidence in children. Highlighting the important role of patients and their families helped decision making, facilitating the work of the medical team. With multidisciplinary
management and close follow-up, they have been able to avoid surgery entering complete clinical remission.
Contact UsFor more information
Contact Us